Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues:
Total revenues	$ 1,464,000	$ 4,026,000
Operating expenses:
Research and development	6,069,000	7,407,000
Selling, general and administrative	11,604,000	10,651,000
Total operating expenses	18,334,000	18,341,000
Loss from operations	(16,870,000)	(14,315,000)
Interest expense		(747,000)
Other income, net	394,000	281,000
Initial loss on common stock warrant and common stock adjustment feature liabilities	(4,000,000)
Change in fair value of common stock warrant and common stock adjustment feature liabilities	9,561,000
Offering costs	(2,555,000)
Loss on extinguishment of debt		(900,000)
Net loss before income taxes	(13,470,000)	(15,681,000)
Income tax provision	(10,000)	(26,000)
Net loss attributable to common stockholders	$ (13,480,000)	$ (15,707,000)
Net loss per share attributable to common stockholders:
Basic and diluted	$ (3.58)	$ (7.28)
Weighted-average number of shares used in per share calculations:
Basic and diluted	3,766,419	2,156,201
Other comprehensive income, net of tax
Unrealized gains on available-for-sale securities		$ 18,000
Other comprehensive income		18,000
Comprehensive loss attributable to common stockholders	$ (13,480,000)	(15,689,000)
Product
Revenues:
Total revenues	657,000	514,000
Operating expenses:
Cost of product revenues	661,000	283,000
License
Revenues:
Total revenues	150,000	1,470,000
Contract Research And Government Grants
Revenues:
Total revenues	$ 657,000	$ 2,042,000